Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

NCT00773747 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

637

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Vorinostat
DRUG: bortezomib
DRUG: placebo to vorinostat

Sponsor

Merck Sharp & Dohme LLC